MET and lung carcinoma: LINC00857 is upregulated in lung cancer cells by a mechanism that involves LINC00857 binding to YBX1, preventing its proteasomal degradation, increasing its nuclear translocation, and promoting MET expression to regulate biological processes such as cell proliferation [61].